BIO Asia–Taiwan 2023 亞洲生技大會

Cracking the ADC Code

Antibody-drug conjugates (ADCs) represent the next generation of game-changing cancer therapies, with potential against a number of other diseases as well. However, the development and manufacturing of these drugs is complex and presents a significant challenge. In this session moderated by Lee-Cheng Liu, president of EirGenix, experts including Edward Hsieh, VP of R&D, Formosa Laboratories; Heidi Wang, OBI Pharma CEO; and aMoon Partner Gur Roshwalb, share their insights on ADC development, regulatory, and investment issues. Register now at BIO Asia–Taiwan 2024 for the opportunity to engage with these experts, get a firsthand view of how the ADC code is being cracked, and understand what this means for ADC development in the Asia-Pacific. Only at BIO Asia–Taiwan 2024!

The New Frontier: Gene and Cell Therapies

The number of gene and cell therapy approvals continues to rise as an increasing number of leading industry players enter the field. However, accessibility and affordability remain a challenge. This session will include updates on development, bioprocessing, affordability, clinical trial design, and investment in gene and cell therapies, with speakers including Dr. John Tsai, CEO of Forcefield Therapeutics and Executive Partner at Syncona; Dr. David Chang, General Manager of Taiwan Bio-Manufacturing Corporation; Dr. Alex Huang, Head of Cell Therapy at BeiGene; Maggie Ho, COO of Amarex Taiwan; and Dr. Gur Roshwalb, Partner at aMoon. Join us for a comprehensive update of this field and a glimpse into its exciting future. Register now at BIO Asia–Taiwan 2024 to claim your seat!